Brevan Howard Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Brevan Howard Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$104K	Sell	12,296 -293,519	-96%	-$2.8M	﹤0.01%	2013
2025 Q4	$3.71M	Buy	305,815 +195,870	+178%	+$2.38M	0.04%	306
2025 Q3	$1.29M	Buy	109,945 +77,617	+240%	+$928K	0.01%	789
2025 Q2	$300K	Buy	+32,328	New	+$253K	﹤0.01%	1551
2025 Q1	–	Sell	-24,078	Closed	-$206K	–	1373
2024 Q4	$206K	Buy	+24,078	New	+$235K	﹤0.01%	906
2024 Q1	–	Sell	-20,121	Closed	-$89.7K	–	1250
2023 Q4	$89.7K	Buy	+20,121	New	+$59.5K	﹤0.01%	970

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Brevan Howard Capital Management's OCUL Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Ocular Therapeutix (OCUL) stake by 96% in Q1 2026, selling an estimated $2.8M and leaving 12,296 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Brevan Howard Capital Management first reported a position in OCUL in Q4 2023 and has held it in 6 quarters since. The position peaked at $3.71M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Brevan Howard Capital Management held 12,296 shares of Ocular Therapeutix worth $104K as of Q1 2026.
Brevan Howard Capital Management sold 293,519 Ocular Therapeutix shares in Q1 2026, an estimated $2.8M.
Ocular Therapeutix made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2013 holding.
Brevan Howard Capital Management first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 6 quarters since.
Brevan Howard Capital Management's Ocular Therapeutix position peaked at $3.71M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.